Visiongain has published a new report on Acromegaly Treatment Market Report to 2031: Forecasts By Disease Type (Ectopic Acromegaly and Pseudo Acromegaly), By Drug Class (Somatostatin Analogs (SSAs) (Somatuline Depot and Other SSAs), Dopamine Agonists (Bromocriptine Mesylate and Other Dopamine Agonists), and Growth Hormone Receptor Antagonist (Somavert)), By Route of Administration (Oral and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online pharmacies) PLUS COVID-19 Recovery Scenarios.
COVID-19 Impact on Acromegaly Treatment Market
The COVID-19 virus is significantly disturbing the care of chronic conditions worldwide. Acromegaly is an uncommon disorder with a frequency extending between 2.8–13.7 cases/100.000 people. Acromegaly management needs a multidisciplinary team of health care professionals (HCPs), primarily comprising neurosurgeons, endocrinologists, and specialized endocrine nurses. Regular sessions, mostly during the initial stages of the disease, and pre/post-surgery are essential. Moreover, injectable somatostatin receptor ligands may require HCP provision to administer. These treatments are expected to be impacted throughout the current pandemic. Visiongain has analyzed the present short and long-term effects on the accountable care solutions market. This report will help to develop strategies for companies by region/countries.
Download Exclusive Sample of Report @https://www.visiongain.com/report/acromegaly-treatment-market/#download_sampe_div
Market Drivers
Increasing Prevalence of Acromegaly
The global acromegaly treatment market is driven by the growing occurrence of genetic disorders arising out of hormonal imbalance. Besides, the growth in hormonal diseases such as endocrine disruption and hypopituitarism is projected to aid the target industry growth in the given timeframe. A survey by the National Organization for Rare Disorders (NORD), acromegaly disease affects men and women equally. It occurs in around 50 to 70 people per million per year.
Ongoing clinical trials
Ongoing research & development and clinical trials for pipeline drugs are pushing the acromegaly treatment industry growth further. Government initiatives about reimbursement circumstances are favoring the target industry growth. For instance, in the U.S. and Europe, many healthcare organizations are contributing to the subsidized pharmaceutical drugs for the treatment of rare diseases including acromegaly.
Novel drugs in the market broaden the options of treatments for doctors and patients. For instance, in March 2019, Critics Pharmaceuticals, Inc. conducted a clinical trial Phase two program comprises two distinct trials: ACROBAT EVOLVE and ACROBAT EDGE. The company is treating the first patients with acromegaly disease. These trials are being conducted simultaneously across the U.S. and the European Union. On the other hand, in March 2019, Pfizer was also conducting clinical trials for SOMAVERT in patients with acromegaly.
Market Opportunities
Growing Awareness and Rising Spending in the Research & Development
The key factors pushing the growth of the acromegaly treatment market are the prevalence of acromegaly disease around the world. Besides, increased disposable income in developing countries such as India and China and rising healthcare spending along with the growing acceptance of non-invasive treatment are also accelerating the growth of the acromegaly treatment market. Moreover, rising awareness among the population and the development of healthcare infrastructure are contributing to the target industry growth.
The rising research & development activities to develop ground-breaking and effective treatments for acromegaly is fueling the target industry growth. In recent times, numerous methods have been advanced to help in the initial diagnosis and observation of acromegaly and its related complications. These developments in acromegaly disease diagnosis have increased the number of patients detected with this illness and give better treatment options. Hence, it is expected to achieve a noteworthy growth rate in the given time frame.
Get Detailed TOC @https://www.visiongain.com/report/acromegaly-treatment-market/#download_sampe_div
How the Acromegaly Treatment Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
- Revenue forecasts to 2031 for Acromegaly Treatment Market, with forecasts for Disease Type, Drug Class, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Acromegaly Treatment market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Acromegaly Treatment Market.
Competitive Landscape
Key players operating in the global Acromegaly Treatment market are Pfizer Inc., Strongbridge Biopharma plc, Aegis Therapeutics LLC, GlaxoSmithKline plc, Novartis Pharma AG, Midatech Pharma PLC, Chiasma Inc., Crinetics Pharmaceuticals Inc, Amryt Pharma plc, Dauntless Pharmaceuticals Inc., Antisense Therapeutics Ltd, and Ipsen Biopharmaceuticals Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Acromegaly Treatment Market and leading companies. You will find data, trends, and predictions.
Find more Visiongain's research reports of Therapeutic Drugs Sector click on the following links:
- Cellular Immunotherapy Market
- Respiratory Drug Delivery Market
- Vaccine Drug Delivery Market
- Acute Kidney Injury Treatment Market
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.